Bristol-Myers Squibb Compnay

Bristol-Myers Squibb Pharma Company

Kimberly A Solomon

Carl P Decicco

Timothy C Burn

Ronald L Magolda

Micky Daniel Tortorella

Robert A Copeland

James M Trzaskos

Elizabeth C Arner

Ruiqin Liu

Michael A Pratta

Fude Yang

Percy H Carter

Peggy Ann Scherle

Qihong Zhao

Joseph E Dinchuk

Paul Davies

The present invention relates to a chimeric chemokine receptor comprising two components: a first sequence comprising the N terminus through the last residue of the seven helix TM region of a first chemokine receptor joined with a second sequence comprising the C terminus of a second chemokine receptor extending from the first intracellular residue of the chemokine receptor to the last residue of the chemokine receptor. The chimeric chemokine receptor can be employed in various applications, such as ligand binding and screening assays and signalling assays. The chimeric chemokine receptor can also form a component of a chemokine receptor modulator design program.

Polynucleotides encoding chimeric chemokine receptors

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu -Ala . The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Aggrecan degrading metallo proteases

Nucleic acids encoding aggrecan degrading metallo proteases

Growing community of inventors

Landenburg, PA, United States of America

Kimberly A Solomon